Novel Therapies for EGFR Exon 20 Insertions and ALK-Positive NSCLC: Developments and Implications
(Dr. Wolf-Dieter Janthur)
15:00
16:00
Immunotherapies in good companionship: where do combination therapies make sense in advanced NSCLC – and where not?
(Prof. Markus Jörger)
16:00
16:30
Pause
16:30
17:30
Targeted therapies in lung cancer
(Prof. Maximilian Hochmair)
17:30
18:30
MSD: How to treat metastatic NSCLC in specific subgroups
(Dr. Alex Friedlaender)
18:30
19:30
AstraZeneca: Adjuvant/ Neo-adjuvant treatment options for NSCLC patients, focus EGFRm
(Dr. Hasna Bouchaab)
19:30
19:35
Round-up and good-byes
This webinar is possible due to the kind support of AstraZenaca, Novartis, MSD, Sanofi-Aventis and Takeda.
Registration
If you already have a user account on our website, please log in. If not, you can register as a guest or register for free. With registration, you always have an overview of all registrations and enjoy all the other benefits of our portal.
